Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

EXAGEN INC. (XGN)

$4.68 -5.45% NASDAQ: XGN · 15-min delayed
  • VISTA, California
  • Public · NASDAQ: XGN
  • 220 employees
  • Founded 2002
$103.6MMarket cap
$66.6MRevenue · FY2025
-$20.0MNet income
220Employees
XGNNASDAQ
2019IPO

About EXAGEN INC.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$66.6M
Net income
-$20.0M
Total assets
$58.0M
Market cap
$103.6M
Gross margin
58.3%
Operating margin
-21.1%
Net margin
-30.0%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$66.6M
Cost of revenue
$27.8M
Gross profit
$38.8M
Operating expenses
$52.9M
Operating income
-$14.1M
Income tax
$51.0K
Net income
-$20.0M
EPS (basic)
$-0.93
EPS (diluted)
$-0.93

Balance sheet

Total assets
$58.0M
Current assets
$48.9M
Total liabilities
$40.6M
Current liabilities
$14.2M
Shareholders’ equity
$17.4M

Cash flow

Operating cash flow
-$13.6M
Investing cash flow
-$626.0K
Financing cash flow
$24.4M
Net cash flow
$10.2M

Statements via Polygon.io (SEC filings)

NASDAQ: XGN
$4.68 -5.45%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$2.65 $11.96

52-week range

Market cap
$103.6M
EPS (diluted)
$-0.93
Shares outstanding
22.1M
Open
Day range
Prev close
Volume
IPO date
Sep 19, 2019

Exagen Inc. (XGN) Stock Price

  • Reported a net loss of $20.0M in FY2025.
  • Revenue grew 38% from FY2021 to FY2025.
  • Gross margin of 58.3%, net margin -30.0%.
  • Trading 61% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review EXAGEN INC..

Write a review
Newsroom

News about EXAGEN INC.

News & sentiment via Polygon.io

FAQ

Exagen Inc.: frequently asked questions

Is Exagen Inc. an American company?

Exagen Inc. is a US-based company headquartered in Vista, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Exagen Inc. headquartered?

Exagen Inc. is headquartered in Vista, California, United States.

Is Exagen Inc. publicly traded?

Yes — Exagen Inc. is a publicly traded company. Its stock trades under the ticker symbol XGN on the NASDAQ.

What does Exagen Inc. do?

Exagen Inc. is an American Medical Devices company in the Health & Beauty sector.

When was Exagen Inc. founded?

Exagen Inc. was founded in 2002.

Explore

Similar companies

Browse all →